Ness, Gregory M DDS

Dr. Yang Liu discusses preclinical studies on the CD24/Siglec-10 pathway, highlighting the development of ONC-781 and ONC-841 antibodies, and their potential in cancer and inflammatory disease treatment.

Bystander naloxone administration increased 43.5% from 2020-2022, with nearly 25,000 opioid overdose patients receiving it before paramedics arrived. Naloxone blocks opioid receptors, reversing overdose effects, but only 3% of patients received it from non-medical bystanders, indicating a need for better education and access.

25% of U.S. adults suspect undiagnosed ADHD, with only 13% discussing it with a doctor. Concerns include self-diagnosis and seeking ineffective treatments. ADHD symptoms vary, affecting focus, behavior, and impulsivity, causing challenges at school, work, and home. Seeking professional evaluation is advised.

Drug studies funded by manufacturers report 50% higher efficacy; Tamar Oostrom's research suggests sponsors selectively publish favorable trials, affecting drug use and patient outcomes.

A new DHODH inhibitor, HOSU-53, developed at Ohio State University, will be tested in a clinical trial for cancer treatment, targeting cancer cell growth by inhibiting a key enzyme involved in metabolic processes.

People often believe they have enough information to make decisions, even when they only have partial data, due to the 'illusion of information adequacy.' This study found that those with incomplete information were more confident in their decisions than those with full information. However, when presented with the missing information, many were willing to change their minds.

John Maraganore, former CEO of Alnylam Pharmaceuticals, launches City Therapeutics, a startup focusing on RNAi-based treatments using tiny RNA molecules called cityRNAs, aiming to target tissues beyond the liver. The company plans to begin human trials for its first drug candidate by early 2026 with $135 million in series A financing.

Alzheimer's disease research saw a decade of stagnation until FDA approved aducanumab in 2021. Since then, therapies like donanemab and lecanemab have shown promise. NKGen's SNK01, an NK cell therapy, and Longeveron's Lomecel-B, an MSC therapy, are in phase 2 trials, demonstrating efficacy and safety. Other novel therapies, including Biogen's BIIB080 and AAV2-BDNF gene therapy, are also in development.

New research by Tamar Oostrom reveals that psychiatric drugs are 50% more effective in clinical trials funded by their manufacturers compared to those funded by other groups, a phenomenon she calls the 'sponsorship effect.' This study, published in the Journal of Political Economy, is the first to directly compare identical drug trials with differing sponsors, finding that publication bias significantly influences results. Oostrom's analysis suggests that preregistration has reduced this effect since 2005, but it does not eliminate the issue entirely, particularly for drugs approved before these practices were implemented.